Compare Bristol-Myers Squibb Co (BMY) vs KraneShares Electric Vehicles and Future Mobility (KARS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs KraneShares Electric Vehicles and Future Mobility — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while KraneShares Electric Vehicles and Future Mobility trades at $30.57. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while KraneShares Electric Vehicles and Future Mobility pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, KraneShares Electric Vehicles and Future Mobility nearer its low. Which is the better fit depends on your goals.
| BMY | KARS | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Sector/Thematic |
52-Week High | $62.37 | $38.01 |
52-Week Low | $42.60 | $23.10 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
KARS trades at $29.72, down 2.8% in the last 24 hours, with technical indicators showing a bearish trend as moving averages signal strong selling pressure. The stock lacks key financial ratio data, but recent news highlights global EV sales growth, particularly in Europe and China, driven by high fuel prices and policy support. However, competition from Chinese automakers and potential US regulatory barriers present challenges.
The outlook for KARS is mixed, with positive industry tailwinds from rising EV adoption offset by technical weakness and competitive risks. Investment opportunities lie in exposure to the expanding EV market, but investors face volatility from geopolitical factors and shifting consumer demand. Caution is warranted given the bearish technical signals and lack of fundamental clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →
